Direct factory supply from our multi-ton synthesis base in Hangzhou. Rigorous quality control, verified purity profiles, and comprehensive analytical documentation for international buyers.
Custom Retatrutide CAS 2381089-83-2: Leading China Suppliers & Factory for Obesity and T2DM Treatment Manufacturer, Pricelist
Custom Dulaglutide CAS NO: 923950-08-7 - Premium China Suppliers and Factory for High-Quality Diabetes Treatment Manufacturers, Quotes
Custom Linaclotide CAS 851199-59-2 - Effective IBS-C and CIC Treatment from Trusted China Suppliers and Factory Quotes, Pricelist
High-Quality Thymalin CAS：63958-90-7 Manufacturers, Service
Custom Cargrilintide CAS 1415456-99-3 - Quality China Suppliers and Factory for Peptide Products Manufacturers, Service
High-Quality Selank CAS: 129954-34-3 Quotes, Pricelist
High-Quality Thymosin Alpha 1 62304-98-7 Manufacturer, Pricelist
Custom Eptifibatide CAS 188627-80-7 - High-Quality China Suppliers and Factory for Platelet Aggregation Inhibition Manufacturers, Pricelist
Unraveling the thermodynamic stability, metabolic selectivity, and industrial synthesis mechanics of the C-terminal hGH fragment 177-191 tyrosine analog.
AOD 9604 represents a truncated synthetic peptide corresponding to the amino acid sequence of the C-terminus of human growth hormone (hGH 177-191) with an additional N-terminal tyrosine residue (Tyr-hGH[177-191]). Unlike full-length somatropin, AOD 9604 selectively triggers beta-3 adrenergic receptor pathways in adipocytes to stimulate fat degradation while avoiding the classical diabetogenic and IGF-1 elevated risks.
The sequence requires a precise intrachain disulfide cross-link between Cysteine residues to maintain its active cyclic loop conformation: [Tyr-Leu-Arg-Ile-Val-Gln-Cys-Arg-Ser-Val-Glu-Gly-Ser-Cys-Gly-Phe]. Improper oxidation during synthesis results in inactive linear conformers, oligomeric aggregates, or mismatched multimers, which severely undermines downstream bioactivity and increases formulation rejection rates.
Commercializing AOD 9604 demands overcoming aggregation along hydrophobic amino acid stretches (Val, Ile, Leu) during automated solid-phase assembly. Thinheal implements specialized microwave-assisted pseudoproline dipeptide building blocks and low-loading CTC resins to maintain continuous linear yield >85%, mitigating steric hindrance and sequence termination before oxidative cyclization.
Navigating global demand spikes, geopolitical raw material constraints, and the strategic consolidation of multi-ton peptide CDMO infrastructures.
Over the last decade, interest in obesity-targeted pharmacotherapies and regenerative joint therapeutics has caused a surge in global peptide demand. As GLP-1 receptor agonists expand commercial awareness of peptide therapeutics, dual-track interest in non-insulinotropic lipolytic fragments like AOD 9604 has elevated procurement volumes from milligram bench reagents to multi-kilogram industrial batches.
Hangzhou Thinheal Pharma-Tech operates within an advanced bio-cluster in Zhejiang, taking advantage of automated DCS synthesis reactors, high-throughput preparative RP-HPLC skids, and proprietary continuous-flow cleaving setups. This integrated platform stabilizes supply continuity against global raw amino acid price volatility, providing predictable per-gram commercial tier quotes.
Synthetic peptides are vulnerable to heat-induced deamidation, sulfoxide formation on methionine/cysteine sites, and moisture absorption. Industrial supply chains require qualified cold-chain transport networks. Our export hubs maintain validated temperature-controlled packaging (-20°C to 4°C) ensuring intact delivery to research institutions, biotech developers, and formulation facilities worldwide.
| Analytical Parameter | AOD 9604 Pharmacopeial Standard | Thinheal CDMO Release Benchmark | Analytical Methodology |
|---|---|---|---|
| Sequence Identification | Tyr-Leu-Arg-Ile-Val-Gln-Cys-Arg-Ser-Val-Glu-Gly-Ser-Cys-Gly-Phe (Disulfide bridge Cys7-Cys14) | Conforms to Primary Sequence Structure | HRMS (ESI-TOF) & Amino Acid Analysis (AAA) |
| HPLC Chromatographic Purity | ≥ 98.0% individual area under curve | ≥ 99.2% (Single Max Impurity < 0.5%) | RP-UPLC C18 (0.1% TFA / Acetonitrile Gradient) |
| Disulfide Connectivity | Intrachain cyclic monomer conformation | Zero free thiol residues / <0.2% dimer formation | Ellman's Reagent Test & LC-MS Mapping |
| Peptide Content (Core Net Active) | ≥ 80.0% (Balance as counter-ion & bound water) | 84.5% – 88.0% Net Active Compound | Nitrogen Elemental Analysis (Kjeldahl / Dumas) |
| Counter-Ion Profiling | Acetate or Trifluoroacetate (TFA) controlled | Acetate Salt (< 0.1% TFA trace upon request) | Ion-Exchange Chromatography (IC) |
| Bacterial Endotoxin & Bioburden | ≤ 10 EU/mg for preclinical injectables | < 0.05 EU/mg (Ultra-Clean Grade) | Kinetic Turbidimetric / Chromogenic LAL Assay |
| Residual Solvents (ICH Q3C) | DMF, DCM, Piperidine, Diethyl Ether within limits | Below Detectable Quantification Thresholds | Headspace Gas Chromatography (GC-MS) |
Meeting the rigorous compliance demands of FDA 21 CFR Part 210/211, EMA Annex 1, and international health authority dossier submissions.
Each lot of AOD 9604 is supplied with complete analytical dossiers: High-Resolution Mass Spectrometry (HRMS) sequence confirmation, 2D RP-HPLC purity profiles, Karl Fischer water titration, residual counter-ion quantification, and microbiological assays.
We provide Open Part Drug Master File (DMF) documentation, TSE/BSE risk declarations, Nitrosamine risk assessments, and elemental impurity profiles in accordance with ICH Q3D to accelerate clinical regulatory submissions across North America and Europe.
While standard solid-phase peptide synthesis leaves residual trifluoroacetate (TFA) salts which can cause cellular cytotoxicity, our downstream processing provides ultra-efficient acetate counter-ion exchange, reducing residual TFA to non-toxic traces (<0.10%).
Our QA testing centers conduct real-time and accelerated stability programs under ICH Q1A(R2) conditions (25°C/60% RH and 40°C/75% RH). We isolate, identify, and report related substance degradation pathways (such as Asp isomerizations and Met oxidations).
Examining the clinical translation pathways of AOD 9604 across metabolic modeling, musculoskeletal tissue engineering, and cosmeceutical research.
In preclinical in vitro and in vivo models of metabolic syndrome, AOD 9604 has been shown to upregulate hormone-sensitive lipase (HSL) activity and accelerate non-esterified fatty acid (NEFA) release from white adipose tissue (WAT). Because it operates without triggering insulin resistance or activating the IGF-1 pathway, it provides researchers with an attractive model compound for isolated fat oxidation studies without confounding glycemic side effects.
Beyond metabolic research, pioneering orthopedic investigations highlight AOD 9604's synergistic chondrogenic potential when combined with hyaluronic acid (HA) matrices. Preclinical trials show enhanced hyaline cartilage regeneration, proteoglycan accumulation, and pain reduction in joint models, positioning this peptide as an active substance for hydrogels and biomaterial-guided joint therapy.
Due to its lower molecular weight (1815.1 Da) compared to native somatropin (22 kDa), AOD 9604 has gained traction in advanced aesthetic dermatology. Formulators explore micro-emulsion and microneedle patch systems targeted at submental fat distribution and localized body contouring, driving commercial demand for high-yield, high-solubility cosmetic grades.
Pioneering sustainable, low-carbon continuous synthesis and high-yield enzymatic cyclization platforms at Thinheal.
Traditional solid-phase synthesis relies heavily on Dimethylformamide (DMF) and N-Methyl-2-pyrrolidone (NMP), which present environmental and regulatory handling challenges. Thinheal is transitioning its peptide synthesis lines toward greener alternative solvents such as Gamma-Valerolactone (GVL) and 2-Methyltetrahydrofuran (2-MeTHF), cutting hazardous effluent by 45% without reducing coupling yields.
By implementing inline Process Analytical Technology (PAT) paired with real-time UV-Vis deprotection monitoring and mass spectrometry feedback loops, our engineers eliminate truncated intermediate accumulation. Continuous-flow synthesis significantly shortens cycle times per amino acid coupling, enabling multi-kilogram scalability within tight production windows.
To improve the efficiency of conventional air or iodine-mediated disulfide cyclization, Thinheal's R&D center is piloting enzyme-catalyzed oxidative folding using engineered protein disulfide isomerases (PDI). This selective approach increases the cyclization yield of monomeric AOD 9604 to over 96%, removing problematic oligomerization side products prior to HPLC loading.
Clear, data-backed answers addressing the analytical, structural, packaging, and commercial pricing queries most critical to qualified API buyers.
Scalable chemical synthesis, specialized regulatory documentation, and dependable batch-to-batch consistency across our therapeutic peptide families.
Custom Vasopressin CAS NO: 50-57-7 Manufacturer, Manufacturers
Custom Mots-C Peptide 16 Amino Acids - China Suppliers & Factory for Enhanced Insulin Sensitivity and Metabolism Manufacturers, Pricelist
High-Quality Setmelanotide CAS 920014-72-8: China Suppliers and Factory for MC4R Agonist in Genetic Obesity Treatment Pricelist, Service
High-Quality Eptifibatide CAS NO: 188627-80-7 - Top China Suppliers and Factory for Platelet Aggregation Inhibition Manufacturer, Pricelist
Custom Eptifibatide (CAS 188627-80-- China Suppliers and Factory for Platelet Aggregation Inhibition Quotes, Service
High-Quality Bremelanotide/PT141 CAS: 189691-06-3 Manufacturer, Quotes
High-Quality Tirzepatide CAS 2023788-19-2: Leading China Suppliers & Factory for Advanced Weight Management Solutions Manufacturer, Quotes
High-Quality Semaglutide CAS 910463-68-2 - Weight Management Solution from Trusted China Suppliers & Factory Manufacturer, Manufacturers
Thin